Product: Phospho-IRAK1 (Thr100) Antibody
Catalog: AF4441
Description: Rabbit polyclonal antibody to Phospho-IRAK1 (Thr100)
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Mol.Wt.: 70-80kDa; 77kD(Calculated).
Uniprot: P51617
RRID: AB_2844505

View similar products>>

   Size Price Inventory
 100ul $350 In stock
 200ul $450 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Clonality:
Polyclonal
Specificity:
Phospho-IRAK1 (Thr100) Antibody detects endogenous levels of IRAK1 only when phosphorylated at Thr100.
RRID:
AB_2844505
Cite Format: Affinity Biosciences Cat# AF4441, RRID:AB_2844505.
Conjugate:
Unconjugated.
Purification:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

AA48924; Il1rak; Interleukin 1 receptor associated kinase 1; Interleukin-1 receptor-associated kinase 1; IRAK; IRAK-1; Irak1; IRAK1-S; IRAK1_HUMAN; mPLK; OTTHUMP00000026014; OTTHUMP00000026015; OTTHUMP00000026020; OTTHUMP00000180621; Pelle; Pelle homolog; Pelle-like protein kinase; Plpk;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
P51617 IRAK1_HUMAN:

Isoform 1 and isoform 2 are ubiquitously expressed in all tissues examined, with isoform 1 being more strongly expressed than isoform 2.

Sequence:
MAGGPGPGEPAAPGAQHFLYEVPPWVMCRFYKVMDALEPADWCQFAALIVRDQTELRLCERSGQRTASVLWPWINRNARVADLVHILTHLQLLRARDIITAWHPPAPLPSPGTTAPRPSSIPAPAEAEAWSPRKLPSSASTFLSPAFPGSQTHSGPELGLVPSPASLWPPPPSPAPSSTKPGPESSVSLLQGARPFPFCWPLCEISRGTHNFSEELKIGEGGFGCVYRAVMRNTVYAVKRLKENADLEWTAVKQSFLTEVEQLSRFRHPNIVDFAGYCAQNGFYCLVYGFLPNGSLEDRLHCQTQACPPLSWPQRLDILLGTARAIQFLHQDSPSLIHGDIKSSNVLLDERLTPKLGDFGLARFSRFAGSSPSQSSMVARTQTVRGTLAYLPEEYIKTGRLAVDTDTFSFGVVVLETLAGQRAVKTHGARTKYLKDLVEEEAEEAGVALRSTQSTLQAGLAADAWAAPIAMQIYKKHLDPRPGPCPPELGLGLGQLACCCLHRRAKRRPPMTQVYERLEKLQAVVAGVPGHSEAASCIPPSPQENSYVSSTGRAHSGAAPWQPLAAPSGASAQAAEQLQRGPNQPVESDESLGGLSAALRSWHLTPSCPLDPAPLREAGCPQGDTAGESSWGSGPGSRPTAVEGLALGSSASSSSEPPQIIINPARQKMVQKLALYEDGALDSLQLLSSSSLPGLGLEQDRQGPEESDEFQS

PTMs - P51617 As Substrate

Site PTM Type Enzyme
T66 Phosphorylation P41743 (PRKCI)
T100 Phosphorylation P31749 (AKT1)
S110 Phosphorylation
R117 Methylation
S131 Phosphorylation
K134 Ubiquitination
T141 Phosphorylation
S144 Phosphorylation
S163 Phosphorylation
S173 Phosphorylation
K180 Ubiquitination
T209 Phosphorylation P51617 (IRAK1)
K239 Acetylation
K242 Ubiquitination
K253 Ubiquitination
K342 Ubiquitination
K355 Ubiquitination
S371 Phosphorylation
S373 Phosphorylation
S375 Phosphorylation
S376 Phosphorylation Q9NWZ3 (IRAK4)
T381 Phosphorylation
T387 Phosphorylation P51617 (IRAK1) , Q9NWZ3 (IRAK4)
K397 Ubiquitination
K435 Ubiquitination
Y515 Phosphorylation
S556 Phosphorylation
S568 Phosphorylation
S591 Phosphorylation
S601 Phosphorylation
T605 Phosphorylation
S650 Phosphorylation
S653 Phosphorylation

PTMs - P51617 As Enzyme

Substrate Site Source
P40763 (STAT3) S727 Uniprot
P51617-2 (IRAK1) T66 Uniprot
P51617 (IRAK1) T209 Uniprot
P51617-4 (IRAK1) S376 Uniprot
P51617 (IRAK1) T387 Uniprot
P58753 (TIRAP) T28 Uniprot
Q96FA3 (PELI1) S70 Uniprot
Q96FA3 (PELI1) S76 Uniprot
Q96FA3 (PELI1) S78 Uniprot
Q96FA3 (PELI1) T80 Uniprot
Q96FA3 (PELI1) S82 Uniprot
Q96FA3 (PELI1) T86 Uniprot
Q96FA3 (PELI1) S125 Uniprot
Q96FA3 (PELI1) T127 Uniprot
Q96FA3 (PELI1) T288 Uniprot
Q96FA3 (PELI1) S293 Uniprot
Q9H4G4 (GLIPR2) S58 Uniprot
Q9HAT8 (PELI2) T290 Uniprot

Research Backgrounds

Function:

Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like receptor (TLR) and IL-1R signaling pathways. Is rapidly recruited by MYD88 to the receptor-signaling complex upon TLR activation. Association with MYD88 leads to IRAK1 phosphorylation by IRAK4 and subsequent autophosphorylation and kinase activation. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to promote pellino-mediated polyubiquitination of IRAK1. Then, the ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and activation. Alternatively, phosphorylates TIRAP to promote its ubiquitination and subsequent degradation. Phosphorylates the interferon regulatory factor 7 (IRF7) to induce its activation and translocation to the nucleus, resulting in transcriptional activation of type I IFN genes, which drive the cell in an antiviral state. When sumoylated, translocates to the nucleus and phosphorylates STAT3.

PTMs:

Following recruitment on the activated receptor complex, phosphorylated on Thr-209, probably by IRAK4, resulting in a conformational change of the kinase domain, allowing further phosphorylations to take place. Thr-387 phosphorylation in the activation loop is required to achieve full enzymatic activity.

Polyubiquitinated by TRAF6 after cell stimulation with IL-1-beta by PELI1, PELI2 and PELI3. Polyubiquitination occurs with polyubiquitin chains linked through 'Lys-63'. Ubiquitination promotes interaction with NEMO/IKBKG. Also sumoylated; leading to nuclear translocation.

Subcellular Location:

Cytoplasm. Nucleus. Lipid droplet.
Note: Translocates to the nucleus when sumoylated. RSAD2/viperin recruits it to the lipid droplet (By similarity).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Isoform 1 and isoform 2 are ubiquitously expressed in all tissues examined, with isoform 1 being more strongly expressed than isoform 2.

Subunit Structure:

Homodimer (By similarity). Forms a complex with TRAF6, PELI1, IRAK4 and MYD88. Direct binding of SMAD6 to PELI1 prevents complex formation and hence negatively regulates IL1R-TLR signaling and eventually NF-kappa-B-mediated gene expression. The TRAF6-PELI1-IRAK4-MYD88 complex recruits MAP3K7/TAK1, TAB1 and TAB2 to mediate NF-kappa-B activation. Interaction with MYD88 recruits IRAK1 to the stimulated receptor complex. Interacts with TOLLIP; this interaction occurs in the cytosol prior to receptor activation. Interacts with IL1RL1. Interacts with PELI1 and TRAF6. Interacts (when polyubiquitinated) with IKBKG/NEMO. Interacts with RSAD2/viperin (By similarity). Interacts with IRAK1BP1 (By similarity). Interacts with PELI2 (By similarity). Interacts with ZC3H12A; this interaction increases the interaction between ZC3H12A and IKBKB/IKKB (By similarity). Interacts with IRAK4. Interacts with PELI3. Interacts with INAVA; the interaction takes place upon PRR stimulation. Interacts (via C-terminus) with NFATC4 (via N-terminus).

(Microbial infection) Interacts with mumps virus protein SH; this interaction inhibits downstream NF-kappa-B pathway activation.

Family&Domains:

The ProST region is composed of many proline and serine residues (more than 20 of each) and some threonines. This region is the site of IRAK-1 hyperphosphorylation.

Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. Pelle subfamily.

Research Fields

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > NF-kappa B signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Bacterial > Pertussis.

· Human Diseases > Infectious diseases: Parasitic > Leishmaniasis.

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Organismal Systems > Immune system > Toll-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.